Last reviewed · How we verify
Cyclopentolate+tropicamide+phenylephrine
Cyclopentolate+tropicamide+phenylephrine is a Anticholinergic + sympathomimetic combination Small molecule drug developed by Pontificia Universidad Catolica de Chile. It is currently FDA-approved for Mydriasis and cycloplegia for ophthalmic examination and diagnostic procedures. Also known as: Cyclogyl, Mydfrin, Mydriacyl.
This combination of three anticholinergic and sympathomimetic agents dilates the pupil and paralyzes accommodation for ophthalmic examination.
This combination of three anticholinergic and sympathomimetic agents dilates the pupil and paralyzes accommodation for ophthalmic examination. Used for Mydriasis and cycloplegia for ophthalmic examination and diagnostic procedures.
At a glance
| Generic name | Cyclopentolate+tropicamide+phenylephrine |
|---|---|
| Also known as | Cyclogyl, Mydfrin, Mydriacyl |
| Sponsor | Pontificia Universidad Catolica de Chile |
| Drug class | Anticholinergic + sympathomimetic combination |
| Target | Muscarinic acetylcholine receptors (M1-M5); alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Cyclopentolate and tropicamide are anticholinergic agents that block muscarinic receptors in the eye, causing mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation). Phenylephrine is an alpha-1 adrenergic agonist that enhances pupil dilation. Together, these agents facilitate comprehensive ophthalmic examination by maximizing pupil opening and temporarily eliminating the eye's focusing ability.
Approved indications
- Mydriasis and cycloplegia for ophthalmic examination and diagnostic procedures
Common side effects
- Transient stinging or irritation
- Blurred vision
- Photophobia
- Increased intraocular pressure
- Systemic anticholinergic effects (rare)
Key clinical trials
- Assessing Patient Comfort, Anxiety, and Satisfaction During CR Comparing Conventional Drops With ROC (NA)
- The Pathophysiology of Orthostatic Hypotension (PHASE1)
- Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study (PHASE4)
- Effect of Intracameral Injection of Mydriatic Plus Anaesthetic Combination on Corneal Endothelial Count in Phaco (PHASE3)
- A New More Efficient Cycloplegia Scheme (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclopentolate+tropicamide+phenylephrine CI brief — competitive landscape report
- Cyclopentolate+tropicamide+phenylephrine updates RSS · CI watch RSS
- Pontificia Universidad Catolica de Chile portfolio CI
Frequently asked questions about Cyclopentolate+tropicamide+phenylephrine
What is Cyclopentolate+tropicamide+phenylephrine?
How does Cyclopentolate+tropicamide+phenylephrine work?
What is Cyclopentolate+tropicamide+phenylephrine used for?
Who makes Cyclopentolate+tropicamide+phenylephrine?
Is Cyclopentolate+tropicamide+phenylephrine also known as anything else?
What drug class is Cyclopentolate+tropicamide+phenylephrine in?
What development phase is Cyclopentolate+tropicamide+phenylephrine in?
What are the side effects of Cyclopentolate+tropicamide+phenylephrine?
What does Cyclopentolate+tropicamide+phenylephrine target?
Related
- Drug class: All Anticholinergic + sympathomimetic combination drugs
- Target: All drugs targeting Muscarinic acetylcholine receptors (M1-M5); alpha-1 adrenergic receptor
- Manufacturer: Pontificia Universidad Catolica de Chile — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Mydriasis and cycloplegia for ophthalmic examination and diagnostic procedures
- Also known as: Cyclogyl, Mydfrin, Mydriacyl
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing